In an effort to clearly understand the state of cardiovascular health in the U.S., the inaugural JACC Cardiovascular Statistics 2026 report offers a comprehensive picture of the major cardiovascular ...

Ready to explore a new professional opportunity? Browse the list below of featured jobs and take the next step in your career! For a filtered job search and to sign up for customized job alerts and ...

We are a young, vibrant section dedicated to adding value to Section members interested in Innovation across the cardiovascular spectrum. Our section is member-driven and focused on all aspects of ...

Chronic consumption of high levels of caffeine a day can lead to an increase in high heart rate and blood pressure that persists after resting from a step test, increasing the risk of cardiovascular ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...

Long-term treatment with beta-blockers may not lower the risk of death or myocardial infarction (MI) in patients with MI, a preserved left ventricular ejection fraction (LVEF) of ≥50% and coronary ...

A single subcutaneous injection of the investigational drug zilebesiran, when added to existing treatment with a standard antihypertensive medication, reduced systolic blood pressure (SBP) by between ...

Ninerafaxstat, a novel cardiac mitotrope that targets energy metabolism, is safe and effective in the treatment of nonobstructive hypertrophic cardiomyopathy (HCM), according to the Phase 2 ...

An ACC Concise Clinical Guidance (CCG) report on "Transthyretin Cardiac Amyloidosis Evaluation and Management" provides updated strategies and best practices for clinicians, taking into account ...

The following are key points from the 2025 ACC/AHA/ASE/ASNC/SCCT/SCMR Advanced Training Statement on Advanced Cardiovascular Imaging: A Report of the ACC Competency ...

The U.S. Food and Drug Administration (FDA) announced on April 15 that Abbott/Thoratec Corp. is recalling the Heartmate II and Heartmate 3 Left Ventricular Assist System (LVAS) due to long-term ...

The following are key points to remember from the American Heart Association/American Stroke Association (AHA/ASA) guideline for the prevention of stroke in patients with stroke and transient ischemic ...